Evidence map›Paper›PMID 29860352›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2018

Lymphocyte-Specific Protein Tyrosine Kinase (LCK) is Involved in the Aryl Hydrocarbon Receptor-Mediated Impairment of Immunoglobulin Secretion in Human Primary B Cells.

Jiajun Zhou, Qiang Zhang, Joseph E Henriquez, Robert B Crawford, Norbert E Kaminski

Open access · bronzeAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jiajun ZhouDepartment of Microbiology & Molecular Genetics.
Qiang ZhangDepartment of Environmental Health, Rollins School of Public Health, Emory University, Georgia 30322.
Joseph E HenriquezInstitute for Integrative Toxicology, Michigan State University, East Lansing, Michigan 48824.
Robert B CrawfordInstitute for Integrative Toxicology, Michigan State University, East Lansing, Michigan 48824.
Norbert E KaminskiDepartment of Microbiology & Molecular Genetics.
Michigan State University · USEmory University · US

Funding

VOLATILE ORGANIC CONTAMINANTS--QUANTIFYING THEIR MOVEMENT IN THE UNSATURATED ZONEP42ES004911 · NIEHS · MICHIGAN STATE UNIVERSITY · PI Timothy R. Zacharewski · 1989 to 2026
$64.9M
Pilot Project ProgramP30ES019776 · NIEHS · EMORY UNIVERSITY · PI Carmen Joseph Marsit · 2013 to 2026
$22.6M
NIEHS NIH HHS P30 ES019776NIEHS NIH HHS P42 ES004911
6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AHR) is a cytosolic ligand-activated transcription factor involved in xenobiotic sensing, cell cycle regulation, and cell development. In humans, the activation of AHR by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a high affinity AHR-ligand, impairs the secretion of immunoglobulin M (IgM) to suppress humoral immunity. However, the mechanisms bridging the activation of AHR and the impairment of IgM secretion by human primary B cells remain poorly understood. Recent transcriptomic analysis revealed upregulation of lymphocyte-specific protein tyrosine kinase (LCK) in AHR-activated human primary B cells. LCK is a well-characterized tyrosine kinase that phosphorylates critical signaling proteins involved in activation and cytokine production in T cells. Conversely, the role of LCK in human primary B cells is not well understood. In the current studies, we have verified the transcriptomic finding by detecting AHR-mediated upregulation of LCK protein in human primary B cells. We also confirmed the role of AHR in the upregulation of LCK by using a specific AHR antagonist, which abolished the AHR-mediated increase of LCK. Furthermore, we have confirmed the role of LCK in the AHR-mediated suppression of IgM by using LCK specific inhibitors, which restored the IgM secretion by human B cells in the presence of TCDD. Collectively, the current studies demonstrate a novel role of LCK in IgM response and provide new insights into the mechanism for AHR-mediated impairment of immunoglobulin secretion by human primary B cells.

Indexed as

Basic Helix-Loop-Helix ProteinsB-LymphocytesCells, CulturedHumansImmunoglobulin MLymphocyte ActivationLymphocyte Specific Protein Tyrosine Kinase p56(lck)Polychlorinated DibenzodioxinsPrimary Cell CultureReceptors, Aryl HydrocarbonAHR protein, humanBasic Helix-Loop-Helix ProteinsImmunoglobulin MLCK protein, humanLymphocyte Specific Protein Tyrosine Kinase p56(lck)Polychlorinated DibenzodioxinsReceptors, Aryl Hydrocarbon

Identifiers

PMID29860352
PMCPMC6659013
OpenAlexW2807339368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.